FDA supplemental approval: Butalbital, Acetaminophen, Caffeine, AND Codeine Phosphate (REMS)

AI Summary

This is a regulatory approval record documenting FDA supplemental authorization of a REMS (Risk Evaluation and Mitigation Strategy) for Fioricet with Codeine, a combination analgesic containing butalbital, acetaminophen, caffeine, and codeine phosphate. The record does not contain clinical trial results, efficacy data, or comparative evidence; it reflects a regulatory requirement for risk management, not a clinical finding.

Plain-language summary

FDA supplemental approval for a Risk Evaluation and Mitigation Strategy (REMS) on an existing combination analgesic; regulatory actions do not report clinical trial data and do not establish efficacy or comparative benefit.

Reported figures

Quoted from the source exactly as published.

Clinical bottom line

This regulatory action does not report clinical evidence or trial outcomes. Clinicians should refer to the product labeling and REMS requirements for information on appropriate use, contraindications, and risk mitigation measures for this opioid-containing combination product.

Caveats

• This is a regulatory record, not a clinical study; no trial results, efficacy data, or safety outcomes are reported.
• The nature and content of the REMS requirements are not detailed in this record.
• No comparative efficacy or safety data versus other analgesics are provided.
• The rationale for the supplemental approval (e.g., new safety concern, risk mitigation refinement) is not stated in the record.

Evidence assessment

Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.

Follow from this

Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.